{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:44:35Z","timestamp":1776660275807,"version":"3.51.2"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018556","name":"Science and Technology Program of Suzhou","doi-asserted-by":"publisher","award":["SLJ201906"],"award-info":[{"award-number":["SLJ201906"]}],"id":[{"id":"10.13039\/501100018556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>The optimal duration of neoadjuvant hormonal therapy (NHT) for high-risk prostate cancer remains controversial. In this study, we evaluated the association between NHT duration and prostate-specific antigen (PSA) kinetics as well as pathological outcomes in patients who underwent extraperitoneal robot-assisted radical prostatectomy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed the data of 72 patients with high-risk prostate cancer who received NHT followed by extraperitoneal robot-assisted radical prostatectomy with pelvic lymph node dissection at a tertiary hospital in 2025. Patients were stratified into the short-term (NHT, \u22643 months; n=41) and long-term (NHT, &amp;gt;3 months; n=31) groups. PSA response, pathological features, and perioperative outcomes were compared between the two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The PSA nadir was significantly lower in patients who underwent long-term NHT than in those who underwent short-term NHT (median 0.02 vs. 0.23 ng\/mL). The proportions of patients in whom PSA levels of &amp;lt;0.1 ng\/mL (67.74% vs. 29.27%) and &amp;lt;0.2 ng\/mL (83.87% vs. 41.46%) were achieved were significantly higher in the long-term group. Pathological analyses demonstrated a significantly lower incidence of extraprostatic extension in patients undergoing long-term NHT (38.71% vs. 70.73%). Operative time and intraoperative blood loss were similar between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In patients with high-risk prostate cancer, undergoing NHT for longer than 3 months was associated with greater suppression of PSA and more favorable pathological outcomes. Particularly, we observed a reduced incidence of extraprostatic extension and no increase in perioperative morbidity. Achieving a substantial PSA response during NHT may be useful as an indicator for optimizing the timing of surgical intervention.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1817402","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:35Z","timestamp":1776658415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between duration of neoadjuvant hormonal therapy and prostate-specific antigen response and pathological outcomes in high-risk prostate cancer undergoing robot-assisted radical prostatectomy"],"prefix":"10.3389","volume":"16","author":[{"given":"Jingsuo","family":"Wang","sequence":"first","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Department of Urology","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfeng","family":"Wu","sequence":"additional","affiliation":[{"name":"The First People\u2019s Hospital of Jintan, Department of Urology","place":["Changzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanao","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Department of Urology","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ouyang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Department of Urology","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Department of Nephrology","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyu","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Soochow University, Department of Urology","place":["Suzhou, Jiangsu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228","article-title":"Prostate cancer: a review","volume":"333","author":"Raychaudhuri","year":"2025","journal-title":"JAMA"},{"key":"B2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3892\/ol.2023.13870","article-title":"Prostate-specific antigen density and preoperative MRI findings as predictors of biochemical recurrence in high-risk and very high-risk prostate cancer","volume":"26","author":"Yang","year":"2023","journal-title":"Oncol Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00497-7","article-title":"Salvage therapy for prostate cancer after radical prostatectomy","volume":"18","author":"Zaorsky","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.20471\/acc.2022.61.s3.7","article-title":"Role of androgen receptor-targeted agents in localized prostate cancer","volume":"61","author":"Murgi\u0107","year":"2022","journal-title":"Acta Clin Croat"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2022.05.029","article-title":"Radical prostatectomy for patients with high-risk, very-high risk, or radiographic suspicion for metastatic prostate cancer: perioperative and early oncologic results from the MUSIC statewide collaborative","volume":"40","author":"Mora","year":"2022","journal-title":"Urol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-021-00514-9","article-title":"Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer","volume":"18","author":"Devos","year":"2021","journal-title":"Nat Rev Urol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1097\/PAP.0000000000000347","article-title":"Neoadjuvant hormonal therapy for prostate cancer: morphologic features and predictive parameters of therapy response","volume":"29","author":"Wang","year":"2022","journal-title":"Adv Anat Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100875","article-title":"A trio of tumor suppressor miRNA downregulates CREB5 dependent transcription to modulate neoadjuvant hormonal therapy sensitivity","volume":"36","author":"Wang","year":"2023","journal-title":"Neoplasia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4307207","article-title":"Effect of neoadjuvant hormone therapy on resection margin and survival prognoses in locally advanced prostate cancer after prostatectomy using propensity-score matching","volume":"2018","author":"Kim","year":"2018","journal-title":"BioMed Res Int"},{"key":"B10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1245\/s10434-018-7035-z","article-title":"Neoadjuvant androgen deprivation therapy prior to radical prostatectomy: recent trends in utilization and association with postoperative surgical margin status","volume":"26","author":"McClintock","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s00345-024-05412-4","article-title":"Neoadjuvant darolutamide plus androgen deprivation therapy for high-risk and locally advanced prostate cancer: a multicenter, open-label, single-arm, phase II trial","volume":"43","author":"Zhang","year":"2025","journal-title":"World J Urol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1284899","article-title":"Androgen deprivation therapy plus apalutamide as neoadjuvant therapy prior radical prostatectomy for patients with unresectable prostate cancer","volume":"14","author":"Wei","year":"2023","journal-title":"Front Pharmacol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2022.09.009","article-title":"ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer","volume":"83","author":"Devos","year":"2023","journal-title":"Eur Urol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5255","article-title":"Neoadjuvant androgen deprivation therapy combined with abiraterone acetate in patients with locally advanced or metastatic prostate cancer: when to perform radical prostatectomy","volume":"12","author":"Xu","year":"2023","journal-title":"Cancer Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1097\/CU9.0000000000000008","article-title":"A prospective study of the effect of testosterone escape on preradiotherapy prostate-specific antigen kinetics in prostate cancer patients undergoing neoadjuvant androgen deprivation therapy","volume":"15","author":"Christie","year":"2021","journal-title":"Curr Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12165321","article-title":"Predictors of extraprostatic extension in patients with prostate cancer","volume":"12","author":"Kim","year":"2023","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.4103\/aja202530","article-title":"Locally advanced prostate cancer treated with neoadjuvant therapy combined with surgery: a multicenter retrospective cohort analysis","volume":"28","author":"Liu","year":"2026","journal-title":"Asian J Androl"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-21-0697","article-title":"Contributions of social factors to disparities in prostate cancer risk profiles among Black men and non-Hispanic White men with prostate cancer in California","volume":"31","author":"Press","year":"2022","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040641","article-title":"Neoadjuvant androgen receptor signaling inhibitors before radical prostatectomy for non-metastatic advanced prostate cancer: a systematic review","volume":"13","author":"Yanagisawa","year":"2023","journal-title":"J Pers Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.21037\/tcr-2025-1-2923","article-title":"Neoadjuvant androgen deprivation therapy with bicalutamide compared to hormonal agents in treating high-risk prostate cancer: a real-world cohort study","volume":"15","author":"Liu","year":"2026","journal-title":"Transl Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.40752","article-title":"Efficacy of degarelix in the neoadjuvant setting in managing locally advanced prostate cancer","volume":"15","author":"Sankaran","year":"2023","journal-title":"Cureus"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132258","article-title":"Treatment intensification prior to radical prostatectomy for clinically localized prostate cancer","volume":"17","author":"Perez Kerkvliet","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23777","article-title":"Differential response to neoadjuvant hormonal therapy in prostate cancer: predictive morphological parameters and molecular markers","volume":"79","author":"Wang","year":"2019","journal-title":"Prostate"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2026.1765517","article-title":"Efficacy of neoadjuvant hormonal therapy combined with robot-assisted radical prostatectomy for oligometastatic prostate cancer: a multicenter retrospective study","volume":"16","author":"Dong","year":"2026","journal-title":"Front Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12957-018-1395-5","article-title":"Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer","volume":"16","author":"Luo","year":"2018","journal-title":"World J Surg Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3390\/life16010029","article-title":"CT-based quantification of prostate volume change after LHRH-agonist androgen deprivation: a prospective, three-reader study for radiotherapy planning","volume":"16","author":"Feltes Ben\u00edtez","year":"2025","journal-title":"Life (Basel)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-007-0204-2","article-title":"Comparative study of the impact of 3- versus 8-month neoadjuvant hormonal therapy on outcome of laparoscopic radical prostatectomy","volume":"133","author":"Pu","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"B28","article-title":"Relationship between prostate volume changes and treatment duration of neoadjuvant androgen deprivation during intensity-modulated radiation therapy for Japanese patients with prostate cancer","volume":"78","author":"Tomida","year":"2016","journal-title":"Nagoya J Med Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/pros.24428","article-title":"Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy","volume":"82","author":"Filon","year":"2022","journal-title":"Prostate"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-1037","article-title":"Modeling androgen deprivation therapy-induced prostate cancer dormancy and its clinical implications","volume":"20","author":"Dong","year":"2022","journal-title":"Mol Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12894-025-01811-w","article-title":"The comparison of outcomes between neoadjuvant novel and classical hormonal therapy in patients with locally advanced prostate cancer: a retrospective study","volume":"25","author":"Yang","year":"2025","journal-title":"BMC Urol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4103\/iju.IJU_115_20","article-title":"Neoadjuvant therapy in high-risk prostate cancer","volume":"36","author":"Ashrafi","year":"2020","journal-title":"Indian J Urol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.23736\/S0393-2249.18.03022-9","article-title":"Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review","volume":"70","author":"Antonelli","year":"2018","journal-title":"Minerva Urol Nefrol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16104-z","article-title":"Comparison of complications and mid-term results for patients who underwent open radical prostatectomy for high-risk and oligometastatic prostate cancer: a cross-sectional study from a tertiary reference center","volume":"31","author":"Beyatl\u0131","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251369037","article-title":"Very deep prostate-specific antigen decline is associated with longer rPFS in patients with metastatic castration-sensitive prostate cancer","volume":"17","author":"Kapar","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2025.01.015","article-title":"Long-term outcomes and prognostic impact of residual cancer burden after intensified neoadjuvant therapy in high-risk prostate cancer","volume":"87","author":"Ravi","year":"2025","journal-title":"Eur Urol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1817402\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:13:36Z","timestamp":1776658416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1817402\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":36,"alternative-id":["10.3389\/fonc.2026.1817402"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1817402","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1817402"}}